Publications


Platform: Year: Target:

Population Pharmacokinetic and Exposure-Response Safety Analyses of Mecbotamab Vedotin (BA3011) in Patients with Advanced Solid Tumors

ASCOMay, 2023

A Novel Dual-Cab Nectin-4 X CD3 Bispecific Antibody Targeting Solid Tumors

American Association for Cancer ResearchApril, 2023

Conditionally Active Biologics Eliminate Senescence Cells in Cancer and Aging

American Association for Cancer ResearchApril, 2023

A Novel Dual-Cab Nectin-4 X CD3 Bispecific Antibody Targeting Solid Tumors

American Association for Cancer ResearchApril, 2023

NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety

American Association for Cancer ResearchApril, 2023

Novel Conditionally Active Bispecific HER2 X CD3 T-Cell Engager Targeting Solid Tumors

American Association for Cancer ResearchApril, 2023

NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety

Antibody Drug Conjugate SummitSeptember, 2022

Interim Safety and Efficacy Results from Phase 1/2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in Patients with Advanced Sarcoma

Connective Tissue Oncology SocietyNovember, 2021

Protein-associated Chemical Switches Differentially Modulate the Binding Activities of Human Apolipoprotein E Isoforms with Their Receptors and with Amyloid Beta Peptides.

Alzheimer’s Association International ConferenceJuly, 2021

Novel Conditionally Active Bispecific EpCAM x CD3 T Cell Engagers Targeting Solid Tumors

American Association for Cancer ResearchApril, 2021

Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors

American Association for Cancer ResearchApril, 2021

Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors

American Association for Cancer ResearchApril, 2020

Novel conditionally active ADCs (CAB ADCs): A novel class of molecules targeting solid tumors

American Association for Cancer ResearchApril, 2020

Novel conditionally active biologic (CAB) antibodies

American Association for Cancer ResearchApril, 2019

A Phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL antibody drug conjugate

American Society of Clinical OncologyJune, 2018

Anti-Tumor Efficacy of BA3011

American Association for Cancer ResearchApril, 2018

Anti-Tumor Efficacy of BA3021

American Association for Cancer ResearchApril, 2018

Novel Conditionally Active Biologic anti-Axl ADC Demonstrates Anti-Tumor Efficacy and Improved Safety Profile

American Association for Cancer ResearchApril, 2016